p53 mediates apoptotic crisis in primary Abelson virus-transformed pre- B cells

Molecular and Cellular Biology

Volumn 19, Issue 7, 1999, Pages 4825-4831

  Unnikrishnan, Indira ^a   Radfar, Arash ^a   Jenab Wolcott, Jenia ^a   Rosenberg, Naomi ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN P19; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ABELSON MURINE LEUKEMIA ONCOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL TRANSFORMATION; LATENT PERIOD; LYMPHOCYTE TRANSFORMATION; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ABELSON MURINE LEUKEMIA VIRUS; ABELSON VIRUS; ANIMALIA; MURINAE; MURINE LEUKEMIA ONCOVIRUS; MURINE LEUKEMIA VIRUS; ONCOVIRINAE;

EID: 0032997265     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.7.4825     Document Type: Article

References (59)

1. Attardi, L. D., S.W. Lowe, J. Brugarolas. and T. Jacks. 1996. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15:3693-3701.
2. Baker, S., S. Markowitz, E. Fearson, J. Wilson, and B. Vogelstein. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-914.
3. Baxter, E. W., K. Blyth, L. A. Donehower, E. R. Cameron, D. E. Onions, and J. C. Neil. 1996. Moloney tnurine leukemia virus-induced lymphomas in p53-deficient mice: Overlapping pathways in tumor development? J. Virol. 70:2095-2100.
4. Blyth, K., A. Terry, M. O'Hara, E. W. Baxter, M. Campbell, M. Stewart, L. A. Donehower, D. E. Onions, J. C. Neil, and E. R. Cameron. 1995. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene 10:1717-1723.
5. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (London) 377:552-556.
6. Calame, K. Personal communication.
7. Chen, X., L. J. Ko, L. Jayaraman, aid C. Prives. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10:2438-2451.
8. Chesebro, B., K. Wehrly, M. Cloyd, W. Britt, J. Portis, J. Collins, and J. Nishio. 1981. Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: Friend-specific and FMR-specific antigens. Virology 112:131-144.
9. Cipl/WAF1 undergo normal development, but are defective in Gl checkpoint control. Cell 82:675-684.
10. ARF tumor suppressor. Genes Dev. 12:2434-2442.
11. Dulic, V., W. K. Kaufmann, S. J. Wilson, T. D. Tisty, E. Lees, J. W. Harper, S. J. Elledge, and S. I. Reed. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023.
12. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAFl, a potential mediator of p53 tumor suppression. Cell 75:817-825.
13. Engelman, A., and N. Rosenberg. 1990. Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity. J. Virol. 64:4242-4251.
14. Friedlander, P., Y. Haupt, C. Prives, and M. Oreo. 1996. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16:4961-4971.
15. Green, P. L., D. A. Kaehler, L. M. Bennett, and R. Risser. 1989. Multiple steps are required for the induction of tumors by Abelson murine leukemia virus. J. Virol. 63:1989-1994.
16. Green, P. L, D. A. Kaehler, and R. Risser. 1987. Clonal dominance and progression in Abelson murine leukemia virus lymphomagenesis. J. Virol. 61:2192-2197.
17. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993 The p21 Cdk-interacting protein Cipl is a potent inhibitor of Gl-cyclin-dependent kinases. Cell 75:805-816.
18. Jenab, J., and N. Rosenberg. Unpublished data.
19. Jones, J. M., U Attardi, L A. Godley, R. Laucirica, D. Medina, T. Jacks, H. E. Varmus, and L. A. Donehower. 1997. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ. 8:829-838.
20. kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-659.
21. Kobayashi, T., U. Consoli, M. Audreeff, H. Shiku, A. B. Deisseroth, and W. Zhang. 1995. Activation of p21WAFl/CIPl expression in a temperature-sensitive mutant of human p53 does not lead to apoptosis. Oncogene 11: 2311-2316.
22. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
23. McGahon, A. J., W. K. Nishioka, S. J. Martin, A. Mabboubi, T. G. Cotter, and D. R. Green. 1995. Regulation of Fas apoptotic cell death by Abl. J. Biol. Chem. 270:22625-22631.
24. Miyashila, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
25. ARF, is a candidate for the plasmacytoma susceptibility locus. Par. Proc. Natl. Acad. Sci. USA 95:2429-2434.
26. Parmar, K., R. C. Huebner, and N. Rosenberg. 1991. Carboxyl-terminal determinants of Abelson protein important for lymphoma induction. J. Virol. 65:6478-6485.
27. Parmar, K., and N. Rosenberg. 1996. Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation. J. Virol. 70:1009-1015.
28. Pomerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H. W. Lee, C. Cordon-Cardo, and R. A. DePinho. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
29. Prives, C. 1998. Signaling to p53: breaking the MDM2-p53 circuit. Cell 95:5-8.
30. Prokocimer, M., and V. Roller. 1994. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 84:2391-2411.
31. Quelle, D. E., F. Zindy, R. A. Ashmun, and C. J. Sherr. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
32. Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation. Proc. Natl. Acad. Sei. USA 95:13194-13199.
33. Reid, S., R. Cross, and E. Snow. 1996. Combined Hoechst 33342 and merocyanin 540 staining to examine murine B cell cycle stage, viability and apoptosis. J Immunol. Methods 192:43-54.
34. Risser, R., D. Kaehler, and W. W. Lamph. 1985. Different genes control the susceptibility of mice to Moloney or Abelson murine leukemia viruses. J. Virol. 55:547-553.
35. Risser, R., M. Potter, and W. P. Rowe. 1978. Abelson virus-induced lymphomagenesis in mice. J. Exp. Med. 148:714-726.
36. Rosenberg, N. 1991. abl oncogenes. Semin. Virol. 2:365-374.
37. Rosenberg, N., and D. Baltimore. 1976. A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J. Exp. Med. 143:1453-1463.
38. Ryan, K., and K. Vousden. 1998. Characterization of structural p53 mutants which show selective defects in apoptosis but no cell cycle arrest. Mol. Cell. Biol. 18:3692-3698.
39. Sabbatini, P., S.-K. Chiou, L. Rao, and E. White. 1995. Modulation of p53-mediated transcriptional repression and apoptosis by adenovirus E1B 19K protein. Mol. Cell. Biol. 15:1060-1070.
40. Sawyers, C. L., W. Callahan, and O. N. Witte. 1992. Dominant negative myc blocks transformation by abl oncogenes. Cell 70:901-910.
41. Serrano, M., A. W. Lin, M. E. McCurrach, D. Beach, and S. W. Lowe. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of P53 and p16INK4a. Cell 88:593-602.
42. Shen, Y. Q., and T. Shenk. 1994. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19K protein or the cellular bcl-2 protein. Proc. Natl. Acad. Sci. USA 91:8940-8944.
43. Sherr, C. J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:2984-2991.
44. Shick, L., J. H. Carman, K. Somasundaram, M. Burrell, D. E. Hill, Y.-X. Zeng, Y. Wang, K. G. Wiman, K. Salhany, T. R. Kadesch, J. G. Monroe, L. A. Donehower, and W. S. El-Deiry. 1997. Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice. Cell Growth Differ. 8:121-131.
45. Skorski, T., M. Nieborowska-Skorska, P. Wlodarski, P. Perrotti, R. Martinez, M. A. Wasik, and B. Calabretta. 1996. Blastic transformation of p53-deficient bone marrow cells by P210 bcr/abl tyrosine kinase. Proc. Natl. Acad. Sci. USA 93:13137-13142.
46. Stein, D. H., and V. Dulic. 1995. Origins of G1 arrest in senescent human diploid fibroblasts. Bioessays 17:537-543.
47. Stott, F. J., S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden, and G. Peters. 1998. The alternative product from the human CDKN2A locus, p 14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
48. Stuppia, L., G. Calabrese, R. Peila, P. Guanciali-Franchi, E. Morizio, A. Spadano, and G. Palka. 1997. p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis. Cancer Genet. Cytogenet. 98:28-35.
49. Thome, K. C., A. Radfar, and N. Rosenberg. 1997. Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. J. Virol. 71:8149-8156.
50. Votja, P. J., and J. C. Barrett. 1995. Genetic analysis of cellular senescence. Biochim. Biophys. Acta 1242:29-41.
51. wap1/cip1. Genes Dev. 8:2817-2830.
52. Wang, J. Y. J. 1993. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr. Opin. Genet. Dev. 3:35-43.
53. Whitlock, C. A., and O. N. Witte. 1981. Abelson virus-infected cells exhibit restricted in vitro growth and low oncogenic potential. J. Virol. 40:577-584.
54. Whitlock, C. A., S. F. Ziegler, and O. N. Witte. 1983. Progression of the transformed phenotype in clonal lines of Abelson virus-infected lymphocytes. Mol. Cell. Biol. 3:596-604.
55. Wolf, D., and V. Rotter. 1984. Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences. Mol. Cell. Biol. 4:1402-1410.
56. Wong, K. K., X. Zou, K. T. Merrell, A. J. Patel, K. B. Marcu, S. Chellappan, and K. Calame. 1995. v-Abl activates c-myc transcription through the E2F site. Mol. Cell. Biol. 15:6535-6544.
57. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature (London) 366: 707-710.
58. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12: 2424-2433.
59. Zou, X., S. Rudchenko, K.-K. Wong, and K. Calame. 1997. Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinases. Genes Dev. 11:654-662.